The biopharmaceutical community faces the need of increased transparency, the global economy, and the evolution of drug development. More>>
Interact with professionals from the pharmaceutical, biotechnology, devices, government, academia, healthcare delivery and related industries. More>>
Tutorial 1 – Cluster Randomization for Drug StudiesTutorial 2 – Risk CommunicationTutorial 3 – Health Canada’s Initiatives to Strengthen the Natural Health Products Program: Focus on “eTools”
Learn more>>
Paul Crotty, General Manager, IMS Canada
Bob Nakagawa, Assistant Deputy Director, Pharmaceutical Services, British Columbia Ministry of Health Services
Role of REBS in the Protection of Human Subjects: Special Populations
Evolving Safety Science
Developments in Biosimilars in Canada, US, Europe, ICH, and WHO
Pharmacogenomics
Pharmacovigilance Operations
Patient Access: What Is Your Role in Facilitating Patient Access?
Site Audits and Site Inspections
Patient Risk Management
Electronic Interface with Health Canada 2009-2010
Ethical Issues in Clinical Trials
New Directions in Safety Outcome Research: DSEN, Sentinel, ENCEPP
Orphan Drugs
The biopharmaceutical community faces the need of increased transparency, the global economy, and the evolution of drug development. More>>